Science Press Release Distribution Services


February 27, 2020 Cardiology 0

Hypertension Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults

Hypertension Canada provides annually updated, evidence-based guidelines for the diagnosis, assessment, prevention, and treatment of hypertension. This year, we introduce 10 new guidelines. Three previous guidelines have been revised and 5 have been removed. Previous age and frailty distinctions have been removed as considerations for when to initiate antihypertensive therapy. [1]

Pulmonary Arterial Hypertension

This review of the mechanism of pulmonary hypertension is focused on pulmonary arterial hypertension, a disorder that can be idiopathic or can occur in association with other disorders, such as infection with the human immunodeficiency virus. The authors suggest that an abnormality involving intracellular signaling mediated by transforming growth factor β underlies the various forms of pulmonary arterial hypertension. [2]

Updated Clinical Classification of Pulmonary Hypertension

In 1998, a clinical classification of pulmonary hypertension (PH) was established, categorizing PH into groups which share similar pathological and hemodynamic characteristics and therapeutic approaches. During the 5th World Symposium held in Nice, France, in 2013, the consensus was reached to maintain the general scheme of previous clinical classifications. However, modifications and updates especially for Group 1 patients (pulmonary arterial hypertension [PAH]) were proposed. The main change was to withdraw persistent pulmonary hypertension of the newborn (PPHN) from Group 1 because this entity carries more differences than similarities with other PAH subgroups. In the current classification, PPHN is now designated number 1. Pulmonary hypertension associated with chronic hemolytic anemia has been moved from Group 1 PAH to Group 5, unclear/multifactorial mechanism. In addition, it was decided to add specific items related to pediatric pulmonary hypertension in order to create a comprehensive, common classification for both adults and children. Therefore, congenital or acquired left-heart inflow/outflow obstructive lesions and congenital cardiomyopathies have been added to Group 2, and segmental pulmonary hypertension has been added to Group 5. Last, there were no changes for Groups 2, 3, and 4. [3]

Hypertension among Type 2 Diabetic Patients in Uyo, South East Nigeria

Objective: The prevalence of non-communicable diseases especially diabetes is increasing in Nigeria. In addition to the other tropical diseases they present an increased load on the healthcare resources of the nation. Diabetic patients with comorbid hypertension are at an increased risk for cardiovascular disease morbidity and mortality. This study was conducted to determine the pattern of hypertension among diabetic patients. [4]

Awareness of Hypertension, Blood Pressure Profile, Anthropometric Parameters and Lifestyle of Adults in Urban and Rural Communities of Sokoto State, Nigeria

Introduction: The increasing prevalence of hypertension and its associated complications have become major health challenges globally despite availability of effective therapies and interventions for the disease. This has been attributed to poor awareness of the disease and the rising prevalence of its risk factors particularly in the developing countries. This study aimed to assess the awareness of hypertension, blood pressure profile, anthropometric parameters and lifestyle of adults in Sokoto State, Nigeria. Methods: A comparative cross-sectional study was conducted among adults (selected by multistage sampling technique) in rural and urban communities of Sokoto State, Nigeria. Data was collected with a set of pretested, interviewer- administered, semi-structured questionnaire, in addition to blood pressure measurement and anthropometry. Data was analyzed using IBM SPSS version 20 statistical package. [5]


[1] Leung, A.A., Daskalopoulou, S.S., Dasgupta, K., McBrien, K., Butalia, S., Zarnke, K.B., Nerenberg, K., Harris, K.C., Nakhla, M., Cloutier, L. and Gelfer, M., 2017. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Canadian Journal of Cardiology33(5), pp.557-576.

[2] Farber, H.W. and Loscalzo, J., 2004. Pulmonary arterial hypertension. New England Journal of Medicine351(16), pp.1655-1665.

[3] Simonneau, G., Gatzoulis, M.A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Sanchez, M.A.G., Kumar, R.K., Landzberg, M., Machado, R.F. and Olschewski, H., 2013. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology62(25 Supplement), pp.D34-D41.

[4] Umoh, V.A., Akpan, E.E. and Idung, A., 2018. Hypertension among Type 2 Diabetic Patients in Uyo, South East Nigeria. Journal of Advances in Medicine and Medical Research, pp.1-6.

[5] Abdulaziz, M.D., Awosan, K.J., Oche, M.O., Yunusa, E.U., Ummar, H.T. and Isah, B.A., 2017. Awareness of hypertension, blood pressure profile, anthropometric parameters and lifestyle of adults in urban and rural communities of Sokoto state, Nigeria. Journal of Advances in Medicine and Medical Research, pp.1-12.

Leave a Reply

Your email address will not be published. Required fields are marked *